Earlier quoted context omitted.
Camelid nanobodies aren't that new, but this is still overselling stuff. I don't like reporting on preprint in general, and this article really doesn't explain the complexities of actually getting some early stage technology like this approved and developed. That's where you end up with the constant barrage of "oh look, another biomedical technology we'll never hear about again" comments, and the amount that this art…
If you take it as science reporting, mainly intended to be of interest to scientists or to people who follow the progress of science , then it's sensible. It's similar to the materials-science reporting they do for battery technologies. These releases coming from University PR departments (this one's from UCSF) aren't really supposed to make it into newspapers for wide consumption. Their target audience is: 1. the pe…
The level of detail in a press release makes it usually pretty useless to a scientist, it hides the important details behind language intended for non-scientists. The abstract of a paper is much more useful if you need to decide whether it is of interest for you at all.